Plain-English translation of NCT06718270 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing CT0596, a new type of treatment that uses your own immune cells (called CAR-T cells) that have been specially modified in the lab to fight blood cancer. Researchers want to find the right dose and learn how safe and effective this treatment is for patients with multiple myeloma or plasma cell leukemia that has stopped responding to other drugs. The medication works by training your immune system to recognize and attack cancer cells.
Multiple myeloma and plasma cell leukemia can become resistant to standard treatments, leaving patients with few options. This trial exists to explore whether this new immune cell approach might offer hope to patients whose cancers have stopped responding to traditional therapies.
You likely qualify if…
You likely don't qualify if…
You would receive the CT0596 cell infusion at the hospital. Researchers will closely monitor you for the first 28 days after infusion to check for side effects and how your body responds. You'll have blood tests, imaging scans, and regular clinic visits to track how well the treatment is working. As part of this early-stage study, your dose may be adjusted based on safety and how your body handles the medication, and you'll continue being followed for up to 15 years to understand the long-term effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China